We are scientists fighting the burden of major acute respiratory virus infections by fostering stakeholder communication and cross-disciplinary research in Europe.

News

All news messages

ESWI activities

9th influenza conference 2023
17 - 20 September 2023
Valencia
www.eswiconference.org
ESWI Airborne
Meet the members in the podcast series ESWI Airborne. These educational and captivating talks give an insight into the fascinating world of respiratory viruses moderated by our host Clare Taylor.
www.eswiairborne.org
ESWI webinar series 2021
How can countries cope with more than one major respiratory virus spreading, while non- pharmaceutical interventions are being loosened week by week?
www.eswiwebinar.org
ESWI Summit 2022
21 June 2022
Brussels & Online
www.respiratoryvirussummit.org
All activities

Education hub

Scientific Papers
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
Jonathan E. Pekar, Andrew Magee, Edyth Parker, Niema Moshiri, Katherine Izhikevich, Jennifer L. Havens, Karthik Gangavarapu, Lorena Mariana, Malpica Serrano, Alexander Crits-Christoph, Nathaniel L. Matteson, Mark Zeller, Joshua I. Levy, Jade C. Wang
|
As 2019 turned into 2020, a coronavirus spilled over from wild animals into people, sparking what has become one of the best documented pandemics to afflict humans.
Scientific Papers
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Alexander A. Cohen, Neeltje van Doremalen, Allison J. Greaney, Hanne Andersen, Ankur SharmaTyler N. Starr, Jennifer R. Keeffe, Chengcheng Fan, Jonathan E. Schulz, Priyanthi N. P. GnanapragasamLeesa M. Kakutani, Anthony P. West Jr., Greg Saturday
|
The COVID-19 pandemic has been ongoing for more than 2 years now, and new variants such as Omicron are less susceptible to the vaccines developed against earlier lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Scientific Papers
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Sourimant J, Lieber CM, Yoon JJ, Toots M, Govindarajan M, Udumula V, Sakamoto K, Natchus MG, Patti J, Vernachio J, Plemper RK.
|
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
Scientific Papers
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA.
|
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
See more

ESWI networks & communities

Influenza Diabetes Community

The Influenza Diabetes Community (IDC) unites scientists, healthcare professionals, patient -and other stakeholder organisations to discuss, share best practices and to network with the objective to raise awareness of the burden of influenza, Covid-19 and RSV in people living with diabetes.

Read more
Young Scientists Network

Some of the best and most innovative ideas come from young scientists, and young scientists are the future of the influenza field. For this reason, ESWI has been actively encouraging the careers of young scientists for many years. 

Read more